These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 15640958

  • 41. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B, International Breast Cancer Study Group.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1571-81. PubMed ID: 17077359
    [Abstract] [Full Text] [Related]

  • 42. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH, Xu BH, Zhang P, Li Q, Zhao LM, Sun Y.
    Zhonghua Zhong Liu Za Zhi; 2007 Feb 01; 29(2):137-40. PubMed ID: 17645853
    [Abstract] [Full Text] [Related]

  • 43. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb 01; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    Breast Cancer Res Treat; 2009 Jul 15; 116(1):153-60. PubMed ID: 18787948
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT, Abreo F, Johnson LW, Li BD, Chu QD.
    Breast Cancer Res Treat; 2009 Jan 15; 113(2):293-9. PubMed ID: 18270814
    [Abstract] [Full Text] [Related]

  • 52. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
    Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P.
    Breast Cancer Res Treat; 2005 Dec 15; 94(3):255-63. PubMed ID: 16267618
    [Abstract] [Full Text] [Related]

  • 53. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P, Chottetanaprasith T, Chatamra K, Sampatanukul P, Wannakrairot P, Rojpornpradit P, Shotelersuk K, Lertbutsayanukul C, Boonjunwetwat D, Vajragupta L.
    J Med Assoc Thai; 2002 Jun 15; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [Abstract] [Full Text] [Related]

  • 54. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
    Colleoni M, Viale G, Goldhirsch A.
    Breast; 2009 Oct 15; 18 Suppl 3():S137-40. PubMed ID: 19914533
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. CT findings of breast cancer with clinically complete response following neoadjuvant chemotherapy--histological correlation.
    Ogawa Y, Nishioka A, Kubota K, Kariya S, Yoshida S, Maeda H, Tanaka Y, Moriki T, Tochika N.
    Oncol Rep; 2003 Oct 15; 10(5):1411-5. PubMed ID: 12883716
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 60. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
    Bao G, Yang DQ, Zhou B, Liu P, Wang S, Cheng L.
    Zhonghua Yi Xue Za Zhi; 2007 Oct 30; 87(40):2843-5. PubMed ID: 18167290
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.